BioNexus Gene Lab Corp. (NASDAQ: BGLC) ("BGLC" or the "Company"), a biotechnology company advancing precision diagnostics and gene-based technologies, today announced the formal completion of its ...

Blood tests that promise to spot cancer before symptoms appear are racing toward clinics, pitched as a simple vial of blood ...

CUPid is what is known as a 'liquid biopsy' - blood tests that look for tiny fragments of cancer DNA in the blood. Developed at The Christie and the University of Manchester, this technique is so ...

Grail Inc. is downgraded from Speculative Buy to Hold after a rapid share price surge from $55 to $100. Click here to read my ...

BioNexus Gene Lab (BGLC) announced the completion of its strategic transaction with Fidelion Diagnostics and Tongshu Biotechnology. With the ...

Diagnosing cancer may soon become easier and less painful thanks to advances in AI-assisted blood and urine tests. Scientists ...

Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection technology, today announced the presentation of multiple lymphoma studies featuring Foresight CLARITY(TM) ...

A new documentary series is putting Manchester's 'pioneering' cancer research in the national spotlight. The episode Clues in ...

Use of MRI-guided focused ultrasound with standard chemotherapy is safe and may improve outcomes for people with glioblastoma ...

A new documentary series is putting Manchester's 'pioneering' cancer research in the national spotlight. The episode Clues in the Blood airs on Channel 4 on December 4 at 10pm and is part of the ...

Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection technology, today announced the presentation of multiple lymphoma studies featuring Foresight CLARITY™ ...

The prostate-specific antigen (PSA) is an enzyme produced by cells in the prostate. One of its roles is to break down the ...